Literature DB >> 26180100

Plasticity of the human visual system after retinal gene therapy in patients with Leber's congenital amaurosis.

Manzar Ashtari1, Hui Zhang2, Philip A Cook3, Laura L Cyckowski4, Kenneth S Shindler5, Kathleen A Marshall6, Puya Aravand5, Arastoo Vossough4, James C Gee3, Albert M Maguire7, Chris I Baker8, Jean Bennett7.   

Abstract

Much of our knowledge of the mechanisms underlying plasticity in the visual cortex in response to visual impairment, vision restoration, and environmental interactions comes from animal studies. We evaluated human brain plasticity in a group of patients with Leber's congenital amaurosis (LCA), who regained vision through gene therapy. Using non-invasive multimodal neuroimaging methods, we demonstrated that reversing blindness with gene therapy promoted long-term structural plasticity in the visual pathways emanating from the treated retina of LCA patients. The data revealed improvements and normalization along the visual fibers corresponding to the site of retinal injection of the gene therapy vector carrying the therapeutic gene in the treated eye compared to the visual pathway for the untreated eye of LCA patients. After gene therapy, the primary visual pathways (for example, geniculostriate fibers) in the treated retina were similar to those of sighted control subjects, whereas the primary visual pathways of the untreated retina continued to deteriorate. Our results suggest that visual experience, enhanced by gene therapy, may be responsible for the reorganization and maturation of synaptic connectivity in the visual pathways of the treated eye in LCA patients. The interactions between the eye and the brain enabled improved and sustained long-term visual function in patients with LCA after gene therapy.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh:

Year:  2015        PMID: 26180100      PMCID: PMC4617524          DOI: 10.1126/scitranslmed.aaa8791

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   19.319


  52 in total

1.  Diffusion-tensor fiber tractography: intraindividual comparison of 3.0-T and 1.5-T MR imaging.

Authors:  Tsutomu Okada; Yukio Miki; Yasutaka Fushimi; Takashi Hanakawa; Mitsunori Kanagaki; Akira Yamamoto; Shin-Ichi Urayama; Hidenao Fukuyama; Masahiro Hiraoka; Kaori Togashi
Journal:  Radiology       Date:  2006-01-05       Impact factor: 11.105

2.  Experience induces structural and biochemical changes in the adult primate brain.

Authors:  Yevgenia Kozorovitskiy; Charles G Gross; Catherine Kopil; Lisa Battaglia; Meghan McBreen; Alexis M Stranahan; Elizabeth Gould
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-18       Impact factor: 11.205

3.  Functional organization of human occipital-callosal fiber tracts.

Authors:  Robert F Dougherty; Michal Ben-Shachar; Roland Bammer; Alyssa A Brewer; Brian A Wandell
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-09       Impact factor: 11.205

4.  Early visual deprivation induces structural plasticity in gray and white matter.

Authors:  Uta Noppeney; Karl J Friston; John Ashburner; Richard Frackowiak; Cathy J Price
Journal:  Curr Biol       Date:  2005-07-12       Impact factor: 10.834

5.  Extensive piano practicing has regionally specific effects on white matter development.

Authors:  Sara L Bengtsson; Zoltán Nagy; Stefan Skare; Lea Forsman; Hans Forssberg; Fredrik Ullén
Journal:  Nat Neurosci       Date:  2005-08-07       Impact factor: 24.884

6.  Statistical diffusion tensor histology reveals regional dysmyelination effects in the shiverer mouse mutant.

Authors:  J Michael Tyszka; Carol Readhead; Elaine L Bearer; Robia G Pautler; Russell E Jacobs
Journal:  Neuroimage       Date:  2005-10-05       Impact factor: 6.556

7.  Demyelination increases radial diffusivity in corpus callosum of mouse brain.

Authors:  Sheng-Kwei Song; Jun Yoshino; Tuan Q Le; Shiow-Jiuan Lin; Shu-Wei Sun; Anne H Cross; Regina C Armstrong
Journal:  Neuroimage       Date:  2005-05-15       Impact factor: 6.556

8.  White matter alterations in cerebral amyloid angiopathy measured by diffusion tensor imaging.

Authors:  David H Salat; Eric E Smith; David S Tuch; Thomas Benner; Vasanth Pappu; Kristin M Schwab; M Edip Gurol; H Diana Rosas; Jonathan Rosand; Steven M Greenberg
Journal:  Stroke       Date:  2006-06-08       Impact factor: 7.914

9.  White matter changes linked to visual recovery after nerve decompression.

Authors:  David A Paul; Elon Gaffin-Cahn; Eric B Hintz; Giscard J Adeclat; Tong Zhu; Zoë R Williams; G Edward Vates; Bradford Z Mahon
Journal:  Sci Transl Med       Date:  2014-12-10       Impact factor: 17.956

10.  Astrocytes promote myelination in response to electrical impulses.

Authors:  Tomoko Ishibashi; Kelly A Dakin; Beth Stevens; Philip R Lee; Serguei V Kozlov; Colin L Stewart; R Douglas Fields
Journal:  Neuron       Date:  2006-03-16       Impact factor: 17.173

View more
  25 in total

1.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.

Authors:  Stephen Russell; Jean Bennett; Jennifer A Wellman; Daniel C Chung; Zi-Fan Yu; Amy Tillman; Janet Wittes; Julie Pappas; Okan Elci; Sarah McCague; Dominique Cross; Kathleen A Marshall; Jean Walshire; Taylor L Kehoe; Hannah Reichert; Maria Davis; Leslie Raffini; Lindsey A George; F Parker Hudson; Laura Dingfield; Xiaosong Zhu; Julia A Haller; Elliott H Sohn; Vinit B Mahajan; Wanda Pfeifer; Michelle Weckmann; Chris Johnson; Dina Gewaily; Arlene Drack; Edwin Stone; Katie Wachtel; Francesca Simonelli; Bart P Leroy; J Fraser Wright; Katherine A High; Albert M Maguire
Journal:  Lancet       Date:  2017-07-14       Impact factor: 79.321

Review 2.  Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna™) in ophthalmology. English version : January 2019.

Authors: 
Journal:  Ophthalmologe       Date:  2020-01       Impact factor: 1.059

Review 3.  Let There Be Light: Gene and Cell Therapy for Blindness.

Authors:  Deniz Dalkara; Olivier Goureau; Katia Marazova; José-Alain Sahel
Journal:  Hum Gene Ther       Date:  2016-02       Impact factor: 5.695

4.  Reprogramming metabolism by targeting sirtuin 6 attenuates retinal degeneration.

Authors:  Lijuan Zhang; Jianhai Du; Sally Justus; Chun-Wei Hsu; Luis Bonet-Ponce; Wen-Hsuan Wu; Yi-Ting Tsai; Wei-Pu Wu; Yading Jia; Jimmy K Duong; Vinit B Mahajan; Chyuan-Sheng Lin; Shuang Wang; James B Hurley; Stephen H Tsang
Journal:  J Clin Invest       Date:  2016-11-14       Impact factor: 14.808

5.  Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.

Authors:  Guylène Le Meur; Pierre Lebranchu; Fanny Billaud; Oumeya Adjali; Sébastien Schmitt; Stéphane Bézieau; Yann Péréon; Romain Valabregue; Catherine Ivan; Christophe Darmon; Philippe Moullier; Fabienne Rolling; Michel Weber
Journal:  Mol Ther       Date:  2017-09-19       Impact factor: 11.454

6.  AAV-Nrf2 Promotes Protection and Recovery in Animal Models of Oxidative Stress.

Authors:  Katharine J Liang; Kenton T Woodard; Mark A Weaver; John Paul Gaylor; Ellen R Weiss; R Jude Samulski
Journal:  Mol Ther       Date:  2017-03-01       Impact factor: 11.454

7.  The Role of the Human Visual Cortex in Assessment of the Long-Term Durability of Retinal Gene Therapy in Follow-on RPE65 Clinical Trial Patients.

Authors:  Manzar Ashtari; Elena S Nikonova; Kathleen A Marshall; Gloria J Young; Puya Aravand; Wei Pan; Gui-Shuang Ying; Aimee E Willett; Mani Mahmoudian; Albert M Maguire; Jean Bennett
Journal:  Ophthalmology       Date:  2017-02-23       Impact factor: 12.079

Review 8.  Visual Cortex Plasticity Following Peripheral Damage To The Visual System: fMRI Evidence.

Authors:  João Lemos; Daniela Pereira; Miguel Castelo-Branco
Journal:  Curr Neurol Neurosci Rep       Date:  2016-10       Impact factor: 5.081

9.  Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.

Authors:  Jean Bennett; Jennifer Wellman; Kathleen A Marshall; Sarah McCague; Manzar Ashtari; Julie DiStefano-Pappas; Okan U Elci; Daniel C Chung; Junwei Sun; J Fraser Wright; Dominique R Cross; Puya Aravand; Laura L Cyckowski; Jeannette L Bennicelli; Federico Mingozzi; Alberto Auricchio; Eric A Pierce; Jason Ruggiero; Bart P Leroy; Francesca Simonelli; Katherine A High; Albert M Maguire
Journal:  Lancet       Date:  2016-06-30       Impact factor: 79.321

Review 10.  Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.

Authors:  Albert M Maguire; Jean Bennett; Elena M Aleman; Bart P Leroy; Tomas S Aleman
Journal:  Mol Ther       Date:  2020-12-03       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.